In a landmark moment for India's space ambitions, Indian astronaut Shubhanshu Shukla has blasted off to the International Space Station (ISS) as part of the Axiom-4 mission , marking the country's return to human spaceflight after a 41-year hiatus . This historic launch from NASA’s Kennedy Space Center in Florida has not only reignited national pride but also officially kickstarted India’s human spaceflight programme . The mission, operated by Axiom Space , includes a four-member international crew that will spend 14 days in orbit , conducting scientific research, outreach programs, and various commercial activities. This momentous occasion places India among a select group of nations capable of sending humans into space and reflects the growing prowess of the Indian space sector . A New Chapter: Shubhanshu Shukla and India’s Astronautical Comeback The last Indian to go to space was Rakesh Sharma in 1984, aboard the Soviet spacecraft Soyuz T-11. Now, in 2025, Shubhanshu...
In recent years, the biotech industry has emerged as a cornerstone of innovation, especially in areas like gene therapy , personalized medicine , and vaccine development . However, this dynamic and promising sector is highly sensitive to government regulations , policy frameworks , and economic signals . Under the Trump administration , the biotech sector witnessed a turbulent journey, driven by policy uncertainty , sudden regulatory shifts, and volatile rhetoric on healthcare pricing reforms . This blog delves into how Trump’s policy ambiguity and decision-making style impacted the biotech industry, contributing to a market slump and investor hesitancy. It also analyzes the broader implications for pharmaceutical innovation , R&D funding , and global biotech partnerships . Trump Administration and Policy Volatility One of the defining features of Donald Trump’s presidency was his unconventional approach to governance . For sectors like biotech, which rely on predictable and ...